[First in a five-part series of the most popular stories on HempToday in 2024]
It has been another turbulent year for the CBD industry as regulatory battles and market shifts dominated headlines. The UK inched forward with a public consultation on CBD approvals, while Italy’s courts sided with stakeholders to suspend a CBD ban. Brazil expanded medical CBD production, though industrial hemp remains sidelined. In the U.S., questions about the FDA’s regulatory role lingered as major players like Charlotte’s Web reported losses. Meanwhile, Japan’s stringent new rules pushed suppliers to adapt quickly to “THC-free” demands. Top stories:
